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Abstract Glutaric aciduria type I (synonym, glutaric acid-
emia type I) is a rare organic aciduria. Untreated patients
characteristically develop dystonia during infancy resulting
in a high morbidity and mortality. The neuropathological
correlate is striatal injury which results from encephalo-
pathic crises precipitated by infectious diseases, immuniza-
tions and surgery during a finite period of brain development,
or develops insidiously without clinically apparent crises.
Glutaric aciduria type I is caused by inherited deficiency of
glutaryl-CoA dehydrogenase which is involved in the
catabolic pathways of L-lysine, L-hydroxylysine and L-
tryptophan. This defect gives rise to elevated glutaric acid,
3-hydroxyglutaric acid, glutaconic acid, and glutarylcarnitine
which can be detected by gas chromatography/mass
spectrometry (organic acids) or tandem mass spectrometry
(acylcarnitines). Glutaric aciduria type I is included in the
panel of diseases that are identified by expanded newborn
screening in some countries. It has been shown that in the
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DOI 10.1007/s10545-011-9289-5majorityofneonatallydiagnosedpatientsstriatalinjurycanbe
prevented by combined metabolic treatment. Metabolic
treatment that includes a low lysine diet, carnitine supple-
mentation and intensified emergency treatment during acute
episodes of intercurrent illness should be introduced and
monitored by an experienced interdisciplinary team. Howev-
er, initiation of treatment after the onset of symptoms is
generally not effective in preventing permanent damage.
Secondary dystonia is often difficult to treat, and the efficacy
of available drugs cannot be predicted precisely in individual
patients. The major aim of this revision is to re-evaluate the
previous diagnostic and therapeutic recommendations for
patients with this disease and incorporate new research
findings into the guideline.
Abbreviations
AA Amino acids
C5DC Glutarylcarnitine
DBS Dried blood spots
GA Glutaric acid
GA-I Glutaric aciduria type I
GCDH Glutaryl-CoA dehydrogenase
GCP Good clinical practice
GC/MS Gas chromatography/mass spectrometry
GDG Guideline developmental group
MS/MS Tandem mass spectrometry
3-OH-GA 3-hydroxyglutaric acid
PKU Phenylketonuria
SIGN Scottish Intercollegiate Guidelines Network
Introduction
Glutaric aciduria type I (synonym, glutaric acidemia type I)
is an autosomal recessive disease caused by inherited
deficiency of glutaryl-CoA dehydrogenase (GCDH, EC
1.3.99.7). It has an estimated prevalence of 1 in 100,000
newborns (Lindner et al. 2004). The GCDH gene is
localized on chromosome 19p13.2 and encodes a flavin
adenine dinucleotide-dependent mitochondrial matrix protein
that is involved in the degradative metabolism of L-lysine, L-
hydroxylysine andL-tryptophan(Fuetal.2004;G r e e n b e r ge t
al. 1995). More than 200 disease-causing mutations are
known (Goodman et al. 1998; Zschocke et al. 2000).
Biochemically, GA-I is characterized by an accumulation
of glutaric acid (GA), 3-hydroxyglutaric acid (3-OH-GA),
glutaconic acid (less frequently), and glutarylcarnitine
(C5DC). These can be detected in body fluids (urine,
plasma, CSF) and tissues by gas chromatography/mass
spectrometry (GC/MS) or electrospray-ionization tandem
mass spectrometry (MS/MS; Baric et al. 1999; Chace et al.
2003). Two biochemically defined subgroups of patients
have been described based on urinary metabolite excretion
of GA, i.e., low and high excretors (Baric et al. 1999). The
low excreting patients have the same risk of developing
striatal injury as the high excretors (Christensen et al. 2004;
Kölker et al. 2006) and must not be considered to have a
“mild” clinical phenotype.
Since the description of two index patients in 1975
(Goodman et al. 1975) more than 500 patients have been
reported worldwide. Four genetic isolates with a high
carrier frequency (up to 1:10) and over-representation of
this disease have been identified, the Amish Community
(Morton et al. 1991), Canadian Oji-Cree natives (Haworth
et al. 1991), the Irish travellers (Naughten et al. 2004), and
the Lumbee in North Carolina (Basinger et al. 2006).
Untreated, approximately 90% of patients will develop
neurological disease during a finite period of brain
development (age 3-36 months) following an acute
encephalopathic crisis often precipitated by gastroenteritis,
intercurrent febrile illness, immunization, or surgical inter-
vention (Hoffmann et al. 1991;K ö l k e re ta l .2006). The
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678 J Inherit Metab Dis (2011) 34:677–694characteristic neurological sequela of these crises is acute
bilateral striatal injury and, subsequently, a complex
movement disorder. Dystonia is the dominant extrapyra-
midal symptom, usually superimposed on axial hypotonia
(Hoffmann et al. 1991; Kyllerman et al. 1994;H e r i n g e re t
al. 2010). With aging, there is a tendency for a fixed
dystonia and akinetic-rigid parkinsonism to develop
(Gitiaux et al. 2008). Morbidity and mortality is high in
patients who have had a crisis (Kyllerman et al. 2004;
Kölker et al. 2006). In 10-20% of patients, neurologic
disease has been demonstrated in the absence of any
documented encephalopathic crisis and has been termed
insidious-onset (Busquets et al. 2000;H o f f m a n ne ta l .
1996) and late-onset (Bähr et al. 2002; Külkens et al.
2005). Two patients with insidious-onset type were
reported in whom striatal injuries had occurred before or
shortly after birth, followed by latent periods of several
months before disability was apparent (Strauss et al.
2007). This study suggests that catabolism in the postnatal
transition period may contribute to the manifestation of
neurological impairment.
During the last three decades therapeutic concepts have
been established and optimized for GA-I. Dietary treatment
in combination with oral supplementation of L-carnitine
and riboflavin (less frequently) during maintenance treat-
ment, and an intensified emergency treatment during
episodes of intercurrent illness are used for the majority
of patients. This treatment strategy has considerably
reduced the frequency of acute encephalopathic crises and
thus morbidity and mortality in early diagnosed patients
(Kölker et al. 2006; Kölker et al. 2007a; Monavari and
Naughten 2000; Strauss et al. 2003; Strauss et al. 2007).
Indeed a recent study has confirmed the effectiveness of
emergency and maintenance therapy (Heringer et al. 2010).
Therefore, GA-I is now considered to be a treatable
condition. Furthermore, studies in Gcdh-deficient mice, an
animal model for GA-I, has provided evidence that low lysine
diet and increased glucose intake reduces the accumulation of
putatively neurotoxic GA and 3-OH-GA in the brain, and that
carnitine supplementation increases the formation of C5DC
andthe brain,liverandplasmaconcentrationsoffreecarnitine
(Sauer et al. 2010;Z i n n a n t ie ta l .2007).
Early clinical diagnosis is hampered by the lack of
characteristic or even pathognomonic signs and symp-
toms before an encephalopathic crisis. Macrocephaly is
found in 75% of patients during infancy (Bjugstad et al.
2000), but is non-specific. Therefore GA-I has been
included in the disease panel of newborn screening in
some countries. DNA-based mutation analysis is used for
the high-risk screening in one cohort of low excretors
(Greenberg et al. 2002).
Significant differences still exist in the approaches used
to diagnose and manage affected patients, and there is a
wide variation in the outcome, particularly in patients
diagnosed presymptomatically (Kölker et al. 2006). The
major aim of this guideline is to re-assess the common
practice and to formulate recommendations for diagnosis
and management of GA-I based on the best evidence
available.
Methods
Guideline development
The guideline development process was initiated following
the 3rd International Workshop on Glutaryl-CoA Dehydro-
genase Deficiency in Heidelberg, Germany (October 2003).
Three further meetings were held in Rimini (May 2004),
Amsterdam (August 2004), and Prague (May 2005).
Working groups were established focusing on the guideline
topics. The members of the guideline development group
(GDG) performed systematic literature review, drafted the
guideline, and discussed it with the GDG members and
external consultants. The guideline draft was reviewed by
external consultants (J. V. Leonard, M. Dixon, R. Surtees†,
M. Kyllerman, B. Wilcken). The final guideline was
published in 2007 (Kölker et al. 2007b) and, subsequently,
it was revised including new literature and feedback from
metabolic experts. The 1st revision was based on dis-
cussions during the 5th guideline meeting in Hamburg
(September 2007). The recent 2nd revision is based on the
6th guideline meeting in San Diego (September 2009). The
GDG consists of Pediatric metabolic specialists and child
neurologists (A. Boneh, A. B. Burlina, S. I. Goodman, A.
Garcia Cazorla, C. R. Greenberg, G. F. Hoffmann, D. M.
Koeller, S. Kölker [chairman], C. Mühlhausen, E. R.
Naughten), chemists (E. Christensen, M. Duran, J. G. Okun
[secretary]), a psychologist (P. Burgard), specialist meta-
bolic dietitians (E. Müller, M. Dixon), and an adult
neurologist (A. P. Burlina).
Systematic literature review
The evidence base for this guideline was similar to the
methodology used by SIGN (Scottish Intercollegiate
Guideline Network; URL: http://www.sign.ac.uk). A sys-
tematic review of the literature on GA-I was carried out
using Medline, Embase, the Cochrane Library, MedLink,
and Orphanet. The years covered were 1975-2010. Internet
searches were also performed on various websites including
international and national societies for inborn errors of
metabolism and those of parent groups. The main searches
were selected and evaluated by a minimum of two members
of the GDG before conclusions were considered as
evidence (Suppl. Tables 1–3).
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To evaluate whether the use of the guideline improves
the outcome of affected individuals with GA-I, some
o ft h eG D Gm e m b e r s( S .K . ,G .F .H . ,P .B . ,C .M . ,E .
M.) performed a prospective follow-up study in
Germany including 52 patients. This study has con-
firmed that the use of therapy recommendations (see
statements #7-9 of this guideline) significantly
improves the outcome of patients diagnosed by
newborn screening (Heringer et al. 2010). It showed
for the first time that both basic metabolic treatment
(low lysine diet, carnitine supplementation) and emer-
gency treatment were clearly beneficial for patients
diagnosed by newborn screening. The beneficial effect
of emergency treatment was more pronounced than that
of maintenance treatment. Furthermore, this study
confirmed that follow-up by a metabolic center is
beneficial, highlighting that treatment and follow-up of
these patients should be performed by an interdisciplin-
ary team of specialists (see statement #6).
To the best of our knowledge, none of the recommen-
dations in the previously published guideline (Kölker et al.
2007b) have been proven invalid. However, based on
clinical studies published in the interim the level of
evidence on which recommendations are based has changed
in some areas. To improve the clarity of the text, the
wording of some statements has been revised and age-
adapted recommendations have been included for metabolic
maintenance and emergency treatment. Furthermore, we
have removed six good clinical practice (GCP) statements
and four low grade recommendations (previous statements
#7, 9-11, 13-16, 21, and 26) reducing the total number of
statements from 31 to 21. This has been made to improve
the readability by providing this information in the text
only and to focus on statements with defined level of
evidence. Five GCP statements with high practical rele-
vance (#1, 10, 11, 17, and 21) have been left in the revised
version.
Diagnostic procedure
Figure 1 summarizes the diagnostic procedure for GA-I.
Differential diagnoses
GA-I is defined as inherited deficiency of GCDH confirmed
by enzyme analysis and/or demonstration of two disease-
causing mutations. All other signs, symptoms and laboratory
abnormalities that are found in affected patients are not
pathognomonic so that the diagnosis should be suspected, but
is not confirmed. These include macrocephaly, acute enceph-
alopathy, basal ganglia injury, white matter disease, move-
ment disorders, subdural and retinal hemorrhage, and isolated
elevation of GA, 3-OH-GA, and C5DC in body fluids. Most
of these in isolation have a wide differential diagnosis,
whereasacombinationoftwoormoreabnormalitiesincreases
the probability for GA-I.
Statement #1. The accurate diagnosis of GA-I has
important practical implications when devising treat-
ment plans and giving appropriate information to
children and their families. The diagnostic work-up
should be done by metabolic specialists (GCP).
Newborn and high-risk screening
Newborn screening disease panel GA-I has been widely
considered a disorder for which newborn screening should be
offered (Pollitt et al. 1997;T h o m a s o ne ta l .1998; Watson et
al. 2006). It has already been included in the disease panels
of expanded newborn screening in some countries.
Major aims Timely diagnosis and start of treatment, i.e.,
before irreversible neurological symptoms occur, results in a
better outcome than start of treatment after the onset of
neurological disease (Bijarnia et al. 2008; Boneh et al. 2008;
Heringer et al. 2010; Hoffmann et al. 1996;K ö l k e re ta l .
2006;K ö l k e re ta l .2007a;N a u g h t e ne ta l .2004; Strauss et al.
2003; Strauss et al. 2007). The aim of newborn and high-risk
screening is to reduce the incidence of neurological disease.
Definitions Population-wide newborn mass screening for
GA-I is performed by MS/MS analysis of acylcarnitines in
newborn blood spots. High-risk screening for GA-I is
performed in neonates with an increased a priori risk.
MS/MS Summarizing results from international screening
laboratories the overall prevalence of GA-I is approximately
1 in 100,000 newborns but varies considerably in different
countries. The diagnostically relevant metabolite is C5DC in
dried blood spots (DBS). In addition, some laboratories are
also using ratios to other measured acylcarnitines (Lindner et
al. 2006) and others repeat the analysis on another bloodspot
from the same DBS as an internal quality control, but this is
a matter for individual laboratories and no recommendations
are given in this guideline. In comparison to DBS, cord
blood testing is of limited value in detecting many inherited
metabolic diseases (Walter et al. 2009). However, this has
not yet been studied systematically in GA-I.
Cut-off levels A C5DC value above the cut-off is considered
positive and requires follow-up. The cut-off level for C5DC
has to be set by each laboratory as it will be influenced by
many factors. Cut-off levels are typically adjusted with more
680 J Inherit Metab Dis (2011) 34:677–694experienceofscreening,aprocessthatislikelytocontinue.At
present, there is no general recommendation for the establish-
ment and setting of cut-off levels.
Diagnostic pitfalls Not all patients can be diagnosed by this
method, as there are patients with a normal or only slightly
increased C5DC concentration in DBS. Patients with GA-I
havebeenmissedbynewbornscreening(Heringeretal.2010;
Smith et al. 2001; Wilcken et al. 2003) or by retrospective
analysis of the newborn blood spots (Gallagher et al.
2005;T r e a c ye ta l .2003), particularly those with a low
excreting phenotype. To circumvent this problem most
A. Newborn
screening
MS/MS
Quantitative
3-OH-GA and GA
analysisin urine
Start treatment
GCDH gene
mutation analysis
GCDH enzyme
analysis
GA-I
established*
Stop treatment
GA-I
excluded
B. Selective
screening
No diagnostic
work-up
recommended
Low excretors 
with known 
mutations?
C5DC > cut-off?
Suspicious signs
and symptoms?
3-OH-GA
(and GA)
elevated?
Two disease-
causing
mutations?
Low or deficient
GCDH activity?
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No**
No
No
No
Fig 1 Diagnostic algorithm for
glutaric aciduria type I. a,
Newborn screening for GA-I is
performed using MS/MS. In low
excretor cohorts with known
mutations, GCDH gene
mutation analysis should be
considered as alternative method
(dotted line). Note that in these
patients treatment should be
started after the identification of
two disease-causing mutations
(*). b, Selective screening
should be initiated if the
diagnosis of GA-I is suspected
clinically or there is a positive
family history. Note that a few
patients with a low-excreting
phenotype may show
(intermittently) normal urinary
excretion of 3-OH-GA (and
GA). If an individual shows
normal 3-OH-GA (and GA)
concentrations in urine (or other
body fluids) but presents with
highly suspicious signs and
symptoms for GA-I, further
diagnostic studies should be
considered but the decision
should be made based on the
individual circumstance (**).
Comment on mutation and
enzyme analysis: Since GCDH
gene analysis is more broadly
available than GCDH enzyme
analysis, and the identification
of two disease-causing muta-
tions not only confirms the
diagnosis but also enables
accurate genetic counselling and
prenatal diagnosis, we
recommend starting with GCDH
gene analysis. However,
depending on local availability
and experience, GCDH
enzyme analysis could be
performed first
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investigations of initially positive screening results such as
analysis of urinary GA and 3-OH-GA. Apparent increases
in C5DC have also been demonstrated in medium-chain
acyl-CoA dehydrogenase deficiency, most probably be-
cause of acylcarnitines of identical mass, such as hydrox-
ydecanoylcarnitine (Napolitano et al. 2004). In patients
with multiple acyl-CoA dehydrogenase deficiency, C5DC
can also be elevated but is accompanied by increased
concentrations of other acylcarnitines. In patients with
renal insufficiency due to acquired or congenital renal
disease, C5DC can also be increased (Hennermann et al.
2009). Since newborn screening in the child reflects the
metabolic state of the mother and infant, newborn screening
laboratories should be aware that elevated C5DC concen-
trations may indicate maternal GA-I (Crombez et al. 2008;
Garcia et al. 2008).
Statement #2. For mass newborn screening for glutaric
aciduria type I determination of C5DC in DBS by MS/
MS should be used (grade B, see Suppl. Table 2).
Alternative methods for high-risk population screening
Clusters of affected patients from genetic isolates with high
carrier frequencies have been identified. The Amish, Irish
travellers and Lumbees have a high excretor phenotype
(Basinger et al. 2006;N a u g h t e ne ta l .2004; Strauss et al.
2003), whereas the Oji-Cree natives are low excretors
(Greenberg et al. 2002). High-risk screening in the Amish
and the Irish travellers was first performed by organic acid
analysis but detection of C5DC in DBS is now used. There
have been no documented false negatives in the Amish and
the Irish travellers populations, whereas false negatives in the
Oji-Cree natives were common when MS/MS was used. As a
consequence, high-risk screening using DBS and a DNA-
based technique specific for the DNA mutation presentinthis
population has been implemented (Greenberg et al. 2002).
Statement #3. In a cohort with a high disease
incidence due to a single common GCDH mutation
and a low excretor phenotype, DNA based methods
should be considered for newborn screening. The use
of MS/MS-based screening in such populations will
likely lead to false negative results (grade D).
Confirmation of a positive screening result
A positive MS/MS screening result should be confirmed by
one or more alternative techniques, including a sensitive
method for quantitative determination of GA and 3-OH-GA
in urine or blood such as GC/MS (Al-Dirbashi et al. 2005;
Baric et al. 1999;S h i g e m a t s ue ta l .2005), mutation
analysis of the GCDH gene, and/or GCDH enzyme analysis
(Christensen 1983; Goodman et al. 1998). A normal urine
or blood 3-OH-GA level will make the diagnosis unlikely,
whereas an elevated urine or blood level of 3-OH-GA
should be followed by mutation analysis and start of
treatment. The finding of two known disease-causing
mutations will establish the diagnosis. If only one or no
known disease-causing mutation or no mutations are found,
GCDH activity should be determined. Low enzyme activity
will again establish the diagnosis, while a normal activity
will exclude it (Fig. 1). Since GCDH gene analysis is more
broadly available than GCDH enzyme analysis and since
the identification of two disease-causing mutations is also
important for prenatal diagnosis and genetic counselling,
we recommend starting with GCDH gene analysis. Accord-
ing to local availability and experience, however, GCDH
enzyme analysis could be performed first.
Statement #4. For the confirmation of a positive
newborn screening result, a specific diagnostic work-
up is required, including a quantitative analysis of GA
and 3-OH-GA in urine or blood, mutation analysis,
and, if feasible, enzyme analysis (grade D).
Selective screening
If an infant or child presents with clinical signs or
symptoms, or neuroradiologic findings (Suppl. Table 4)o f
GA-I, a diagnostic evaluation should be undertaken
regardless of whether the child was previously evaluated
in a newborn screening programme. The major disadvan-
tage of relying on clinical suspicion before initiating testing
is that there is no single pathognomonic sign or symptom
that will reliably identify affected patients before irrevers-
ible neurological damage occurs. A few asymptomatic
patients have been diagnosed in the course of a diagnostic
work-up for macrocephaly (Kölker et al. 2006), but this is a
non-specific sign and has a low predictive value. The only
effective way to identify patients with a low a priori risk is
via newborn screening.
Methods Quantitative organic acid analysis has some
advantages for selective screening compared to MS/MS
analysis of acylcarnitines in DBS or plasma (higher
sensitivity and specificity), particularly in patients with
secondary carnitine depletion, and is therefore usually
the first line method for selective screening (Baric et al.
1999). False positive test results have been observed
(Suppl. Table 5); the separation of 3-OH-GA from 2-
hydroxyglutaric acid may be cumbersome. The analysis of
urinary C5DC is also helpful since it may remain elevated
in patients with secondary carnitine depletion, and in low
excretors (Tortorelli et al. 2005). Analysis of GCDH
enzyme activity in fibroblasts or leukocytes is the ‘gold
standard’ for confirming the diagnosis (Christensen 1983).
682 J Inherit Metab Dis (2011) 34:677–694Mutation analysis of the GCDH gene has a sensitivity of
98-99% (Zschocke et al. 2000). The use of in vivo loading
tests using lysine or prolonged fasting tests is not
recommended as age-matched controls are usually not
available and the tests are potentially harmful.
Statement #5. In patients with signs and symptoms of
glutaric aciduria type I, a specific diagnostic work-up
should include quantitative analysis of GA and 3-OH-
GA in urine or blood, GCDH gene mutation analysis,
and/or enzyme analysis (grade D).
Cascade screening
Cascade screening is the systematic programme of approach-
ing relatives of index patients enabling the identification of
asymptomatic patients and of carriers. It is most likely to be
valuable in inbred communities and may prevent the
manifestation of neurologic disease in patients born before
the start of, or missed by, C5DC screening. However, cascade
screeningmaynotbenecessaryoncenewbornmassscreening
has beenestablished inacountry. Despite the preventivevalue
of the information, relatives may object to cascade
screening insisting on their right ‘not to know’ that they
are at risk (de Wert 2005). However, it is important to screen
siblings of identified patients.
Metabolic maintenance treatment
Table 1 summarizes recommended best practice on meta-
bolic maintenance treatment in GA-I based on the clinical
experience of the GDG.
Treatment should be started before confirmation of the
diagnosis by enzyme and/or mutation analysis where there is
strong suspicion of GA-I (Fig. 1). It has been demonstrated
recently that implementation of metabolic treatment and
regular follow-up by specialized metabolic centers improves
the outcome of patients with GA-I (Heringer et al. 2010).
Statement #6. Metabolic treatment should be imple-
mented by an interdisciplinary team that includes
metabolic pediatricians, dietitians, and nurses. Parents
and patients should have regular training and written
treatment protocols (grade C).
Treatment and outcome
Most patients remain asymptomatic if treatment is started in
the newborn period (Bijarnia et al. 2008; Boneh et al. 2008;
Heringer et al. 2010; Kölker et al. 2007a; Naughten et al.
2004; Strauss et al. 2003). Dietary treatment in combination
with carnitine and emergency treatment has been demon-
strated to be effective in preventing neurological disease
(Kölker et al. 2007b). Recently the relative efficacy of each
single component of this therapy has been evaluated,
demonstrating that outcome was best in patients who
received all three interventions (low lysine diet, carnitine,
and emergency treatment), and that deviations from basic
metabolic treatment (low lysine diet, carnitine) resulted in
an intermediate outcome. Disregard of emergency treatment
recommendations was associated with a poor outcome
(Heringer et al. 2010). The results of this study are
supported by the highest level of evidence available
regarding GA-I (i.e., 2
++), and confirm previous observa-
tions suggesting that emergency treatment is the most
Table 1 Metabolic maintenance treatment (protocol proposed by GDG). If normal growth and development are not achieved these
recommendations should be modified according to individual needs
Treatment Age
0–6 months 7–12 months 1–3 years 4–6 years > 6 years
1. Low lysine diet
Lysine (from natural protein)
a mg/kg per day 100 90 80-60 60-50 Avoid excessive intake of natural
protein; use natural protein with a
low lysine content; according to
‘safe levels’ (Suppl. Table 6)
Amino acid mixtures (protein)
b g/kg per day 1.3-0.8 1.0-0.8 0.8 0.8
Energy kcal/kg per day 115-80 95-80 95-80 90-80
2. Micronutrients
c % ≥ 100 ≥ 100 ≥ 100 ≥ 100 ≥ 100
3. Carnitine mg/kg per day 100 100 100 100-50 30-50
aThe lysine/protein ratio varies considerably in natural food and thus natural protein intake in children on a low lysine diet is dependent on the
natural protein source. The natural protein intake is relatively high if patients predominantly use sources of natural protein with a low lysine
content.
bLysine-free, tryptophan-reduced amino acid mixtures should be supplemented with minerals and micronutrients as required to maintain normal
levels. Adequate intake of essential amino acids is provided from natural protein and lysine-free, tryptophan-reduced amino acid supplements. The
amount of amino acid supplements is adjusted to reach at least the ‘safe levels’ (Dewey et al. 1996; see also Suppl. Table 6).
cAccording to international dietary recommendations.
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al. 2007a, b; Naughten et al. 2004; Strauss et al. 2007).
Since striatal injury occurs acutely or insidiously until age
6 years, treatment recommendations for maintenance and
emergency treatment are strict for patients at ages 0-6 years
and relaxed for patients older than 6 years of life.
In contrast to patients identified presymptomatically,
outcome in GA-I is poor when diagnosed after the manifesta-
tion of neurological disease (Busquets et al. 2000; Bjugstad et
al. 2000;H o f f m a n ne ta l .1996; Kyllerman et al. 2004). The
value of metabolic treatment is unclear in patients with severe
neurological symptoms, but individual patients may benefit
by prevention of progressive neurological deteroriation
(Bjugstad et al. 2000;H o f f m a n ne ta l .1996; Kölker et al.
2006; Strauss et al. 2003).
Dietary treatment
Use of dietary recommendations and individualization
of treatment Dietary recommendations outlining the age-
dependent needs of a growing child have been developed
by international organizations (Suppl. Tables 6, 7). They are
usually set to the safe level. Note that in Suppl. Table 6
protein recommendations for infants and children may vary
significantly between the recommendations due to the use
of different reference proteins and the use of average versus
safe levels. Standard dietary recommendations can form the
basis for dietary treatment in GA-I but due to discrepant
and varying requirements for nutrients and energy in
symptomatic children they should be adjusted to the
individual (Müller and Kölker 2004; Yannicelli et al.
1994). There is still limited practical experience with the
use of more recent recommendations such as the report of
the joint WHO/FAO/UNU expert consultation (World
Health Organization 2007).
Low lysine diet Dietary treatment for GA-I aims to reduce
the intake of lysine, the quantitatively most relevant
amino acid precursor of neurotoxic GA and 3-OH-GA,
while maintaining sufficient intake of essential nutrients
and energy substrates. Many metabolic centers limit the
total protein intake to reduce lysine intake rather than
limiting lysine intake per se. This is often for practical
reasons such as the lack of precise or recent data on
lysine contents of foods in their country. However, since
the lysine content varies considerably in different natural
proteins, eg 2-4% (lysine/protein) in cereals and 9%
(lysine/protein) in fish, the daily lysine intake may be
less well controlled by calculation of protein intake
rather than lysine intake (Suppl. Table 8). This may also
increase the risk of essential amino acid deficiencies,
including tryptophan, which is associated with neurolog-
ical dysfunction such as irritability and sleep irregularity
(Hoffmann et al. 1991). Low lysine diet is often combined
with the use of lysine-free, tryptophan-reduced amino
acids (AA) supplements. These supplements are given
with the aim of preventing malnutrition by providing
essential amino acids and (depending on the product) also
minerals, trace elements and vitamins. Although in some
studies (Busquets et al. 2000;K ö l k e re ta l .2006;K ö l k e re t
al. 2007a;H e r i n g e re ta l .2010; Naughten et al. 2004)t h e
majority of patients on a low lysine diet also received
lysine-free, tryptophan-reduced amino acids supplements,
whether a low lysine diet is more effective and safer if it is
combined with these supplements has not been systemat-
ically studied.
The use of a diet based on lysine intake combined
with lysine-free, tryptophan-reduced AA supplements to
maintain adequate total protein intake has been associat-
ed with the most favorable neurologic outcome and
normal growth in some studies (Heringer et al. 2010;
Kölker et al. 2006;K ö l k e re ta l .2007a), whereas other
studies in smaller cohorts have not found a significant
effect of dietary treatment on the outcome (Strauss et al.
2007; Boneh et al. 2008). A possible explanation for this
discrepancy is that larger patient groups are required for
the delineation of a beneficial effect of dietary treatment
from the somewhat stronger effect of emergency treat-
ment. The prescription of dietary treatment should be
adjusted to the experience of metabolic centers. For
instance, prescribing a total amount of natural protein
based on international dietary recommendations in com-
bination with an exchange system (i.e., one exchange is
the amount of food which provides 1 g protein) may be
used instead of calculation of lysine intake. This method
will reduce overall lysine intake but is likely to be
associated with more day to day variability.
Infant feeding Breast feeding has proven benefits for
infants but, with the exception of phenylketonuria (PKU),
there are few published reports for inherited metabolic
diseases (Huner et al. 2005; MacDonald et al. 2006).
However, breast feeding in infants with GA-I should be
encouraged. It can be performed in analogy to PKU
(Francis and Smith 1981) using breastfeeding on demand
with special lysine-free and tryptophan-reduced infant
formula given prior to breastfeeds thus limiting lysine
intake. Although other safe methods for incorporation of
breastfeeding into treatment of PKU have been established
(van Rijn et al. 2003), they have not been systematically
studied in GA-I. Since the amount of lysine in breastmilk is
known (86 mg per 100 mL, “Bundeslebensmittelschlüssel
II.3”; www.bls.nvs2.de), daily lysine intake can be estimat-
ed when breast milk is the only source of natural protein.
Bottle feeding can be based on actual lysine intake as the
lysine content of infant formula is known. However,
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formula may increase the risk for nutritional deficiencies.
Statement #7. A low lysine diet (i.e., reducing lysine
intake to a safe requirement) with or without
additional administration of lysine-free, tryptophan-
reduced amino acids supplements should be used for
dietary treatment, in particular in asymptomatic
patients up to age 6 years (grade C).
Dietary treatment after age 6 years The long-term outcome
in patients with GA-I is not well documented. Besides the
injury associated with acute encephalopathic crises, there is
also evidence of chronic neurologic deterioriation in late-
onset and insidious-onset patients with no documented
crisis (Bähr et al. 2002; Harting et al. 2009; Külkens et al.
2005). With the exception of single case reports that have
suggested a potential benefit to dietary treatment after age
6 years, its efficacy has not been systematically evaluated.
However, there is evidence for ongoing extrastriatal
neuroradiological changes after age 6 years (Harting et al.
2009), and though the clinical relevance of these changes is
unclear, it may be advisable to continue dietary treatment
using a less stringent protocol than that used prior to age
6 years.
Children with feeding problems Dystonic children are at
increased risk for malnutrition (Müller and Kölker 2004;
Yannicelli et al. 1994), mobility and feedings skills are
important prognostic parameters (Kölker et al. 2006).
Children with feeding problems therefore need skilled
metabolic dietetic supervision. They often require tube
and overnight feeding and pharmacotherapy or surgery (i.e.,
fundoplication, gastrostomy, jejunostomy) to maintain
adequate nutrition.
Education The efficacy of the low lysine diet critically
depends upon adequate provision of information and
education of parents, patients and caregivers. It is essential
they receive continued support and education.
Pharmacotherapy
Carnitine supplementation Secondary carnitine depletion
in plasma is common in untreated patients (Lipkin et al.
1988; Seccombe et al. 1986), whereas the concomitant
intracellular carnitine concentrations are unknown. Conju-
gation of glutaryl-CoA to form non-toxic C5DC is
considered a physiological detoxification, and proposed to
replenish the intracellular CoA pool (Seccombe et al. 1986).
L-Carnitine supplementation alone or in combination with a
low lysine diet is thought to contribute to improved
outcome in patients identified during the newborn period
(Heringer et al. 2010; Kölker et al. 2007a; Strauss et al.
2003). However, no randomized controlled studies are
available (Nasser et al. 2009; Walter 2003). To prevent or
reverse secondary carnitine depletion, an initial oral dosage
of 100 mg L-carnitine/kg per day is commonly used
(Kölker et al. 2007a; Strauss et al. 2003). The dosage is
then adjusted to maintain the plasma free L-carnitine
concentration in the normal range. Usually, oral L-carnitine
supplementation can be reduced to 50 mg/kg per day in
children at age 6 years, and further reduced in adolescents
and adults. A reduction of L-carnitine can be considered if
side effects, such as diarrhoea and fish odor, occur.
Statement #8. L-Carnitine should be supplemented in
patients with glutaric aciduria type I and should be
continued lifelong (grade C).
Riboflavin Although an improvement of biochemical
parameters has been suggested in single patients (Brandt
et al. 1979; Lipkin et al. 1988), there is no firm evidence
that riboflavin improves the neurological outcome of this
disease (Kölker et al. 2006). Riboflavin responsiveness in
GA-I appears to be exceedingly rare (Chalmers et al. 2006).
There is no standardized protocol of how to assess
riboflavin sensitivity, or means to predict it based on
GCDH gene mutation analysis.
Neuroprotective agents There is no firm evidence that
administration of other drugs, such as phenobarbitone, N-
acetylcysteine, creatine monohydrate, topiramate, glutamate
receptor antagonists and antioxidants are beneficial
(Greenberg et al. 2002; Kyllerman et al. 1994;K y l l e r m a n
et al. 2004; Strauss et al. 2003), though theoretically they
may appear to be of value.
Emergency treatment
Routine treatment does not protect against encephalopathic
crises,soitiscrucialtouseanintensifiedemergencytreatment
protocol when the patient is thought to be at risk (Heringer et
al. 2010; Monavari and Naughten 2000; Strauss et al. 2007).
The decision to institute emergency treatment should be
made very freely with a low index of suspicion.
Basic principles of emergency treatment
Emergency treatment follows the basic treatment principles of
metabolic diseases of the intoxication type (Dixon and
Leonard 1992; Prietsch et al. 2002): (1) the prevention or
reversal of a catabolic state by administration of a high-
energy intake (plus insulin to control for hyperglycemia if
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transient reduction or omission of natural protein for 24 (-48)
hours; (3) amplification of physiological detoxification
mechanisms and prevention of secondary carnitine depletion
by L-carnitine supplementation and (4) maintenance of
normal fluid, electrolytes, and pH status via enteral of IV
fluids. Non-adherence to previously described emergency
treatment recommendations (Kölker et al. 2007b) has been
associated with a high probability of developing striatal
injury (Heringer et al. 2010).
Management of emergency treatment
Preventive care Delayed start of the emergency regimen
can have serious consequences. The causes of delay are
many and varied; all of these should be identified
systematically (Table 2). For example, plans for metabolic
management during and after elective surgery should be
made ahead in consultation with the surgical team prior to
the procedure.
Start of emergency treatment The possibility of a crisis
should be suspected during each infectious disease, immu-
nization, or surgical intervention during the vulnerable
period (age 0-6 years). In particular, conditions accelerating
catabolism, such as repeated vomiting and diarrhoea (with
or without fever), and the manifestation of severe neuro-
logical symptoms (i.e., hypotonia, irritability, rigor, dysto-
nia, reduced consciousness) should be considered as
alarming symptoms. With increasing age, and in particular
after age 6 years, the risk of acute neurological insult
appears to be much reduced (Bjugstad et al. 2000; Kölker et
al. 2006; Strauss et al. 2003). Emergency treatment should
aim to start before the onset of alarming neurological
symptoms (Heringer et al. 2010; Strauss et al. 2007).
Statement #9. Emergency treatment should start without
delay and should be performed aggressively during
febrile illness, surgery and immunization within the
vulnerable period for acute encephalopathic crises (up
to age 6 years) (grade B).
Table 2 Strategies to prevent delayed start of emergency treatment
Topic Proposed strategies to avoid delay
Education and training of
parents
Parents should be informed in detail about the natural history and the particular risks of glutaric aciduria type I, in
particular the manifestation and neurological sequels of an acute encephalopathic crisis. They should be instructed
precisely about the management of maintenance and emergency treatment and this knowledge should be reinforced
during regular visits at a metabolic center.
Treatment protocols Written protocols for maintenance and emergency treatment should be given to all who may be involved (parents,
metabolic centers, local hospitals) and kept updated. Parents should also receive an emergency card (preferably
laminated) summarizing the key information on glutaric aciduria type I and basic principles of treatment. The
telephone number of the responsible metabolic center/physician should be written on the protocol and the
emergency card. Parents should take their emergency instructions and supplies of maltodextran and AA
supplements when going to hospital.
Supplies Parents should be advised always to maintain adequate supplies of specialized dietetic products (maltodextran,
lysine-free, tryptophan-reduced amino acid mixtures) and drugs required for maintenance treatment and emergency
treatment at home.
Local hospital or
pediatrician
The closest hospital/pediatrician should be clearly instructed if glutaric aciduria type I has been newly diagnosed in a
child. Key information (including written treatment protocols) should be provided to the local hospital/pediatrician
without delay and before inpatient emergency treatment might be necessary. Inpatient emergency treatment should
be started immediately in the closest hospital if necessary and follows the supervision of the responsible metabolic
center which should be contacted without delay.
Holidays Metabolic specialists/centers in the vicinity of the holiday resort should be informed in writing about the disease and
the recent treatment before the start of the holidays. The emergency card and treatment protocols should be
translated before the start of the holidarys if necessary.
Infectious diseases During infectious disease the responsible metabolic center/metabolic specialists should be informed (by parents or
local hospitals/pediatricians) without delay to allow supervision of the emergency management. Parents should be
instructed to call their doctor and/or metabolic consultant as soon as a temperature of 38.5°C is noted and an
intercurrent illness is suspected either, an upper respiratory infection, gastrointestinal infection or if increased
irritability develops.
Vomiting/diarrhoea Vomiting and diarrhoea is particularly dangerous – even in the absence of fever. Please follow the recommendations
for “infectious diseases” (see above).
Surgery If a surgical intervention is planned, the responsible metabolic center/specialist should be informed before such
interventions to discuss the specific risks of affected patients with surgeons and anaesthesiologists, to recommend a
protocol for the postsurgical metabolic management and to allow supervision of this period. If possible, the
postsurgical metabolic management should be performed in a metabolic center. In general, fasting should be
avoided, glucose infusions applied, and carnitine dosage doubled.
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less than 38.5°C and the child is not vomiting, is tolerating
the formulae and if there is no alteration in level of
consciousness or any other alarming neurological symptoms,
a trial treatment period at home of up to 12 hours is
recommended. During this time period patients should be
reassessed every two hours regarding state of consciousness,
fever, and feed tolerance. If parents are adequately trained,
maltodextran solutions can be applied via nastrogastric,
gastrostomy, or jejunostomy tube to achieve overnight and
optimal energy intakes. If body temperature rises above
38.5°C, antipyretics such as ibuprofen or paracetamol should
be administered. If emergency treatment at home is
successful and no worrying signs or symptoms occur during
this period, maintenance treatment should be reintroduced
stepwise during the next 48 (-72) h. Table 3 summarizes
recommended best practice based on the clinical experience
of the GDG.
Emergency treatment at hospital If the patient has recurrent
vomiting, recurrent diarrhoea, reduced intake of nutrients,
spiking temperature or concerning neurological signs, emer-
gency therapy at home is not safe and the patient should be
transferred immediately to a metabolic center or the closest
hospital(preferably under the guidanceofa metabolic center).
Athospitalthechildshouldbeseenimmediately,assessedand
treatment begun. Table 4 summarizes recommended best
practice based on the clinical experience of the GDG.
Emergency treatment after age 6 years Although encepha-
lopathic crises are extremely rare if they occur at all after age
6years(Bjugstadetal.2000;K ö l k e re ta l .2006; Strauss et al.
2003), it cannot be concluded that febrile illness, surgery and
immunization are completely harmless at this age group.
Statement #10. Emergency treatment in children after
age 6 years should be considered at least during severe
illness. It should be performed similarly to that in the age
group 0-6 years with adaptation to the individual (GCP).
Management of neurologic complications
The major neurological complications in GA-I are the
manifestation of a complex movement disorder and
subdural hemorrhage. Epileptic seizures and arachnoid
cysts may also be observed.
Management of movement disorders
Striatal injury induces a variable clinical picture. Dystonia
superimposed on axial hypotonia is usually the dominant
extrapyramidal symptom (Hoffmann et al. 1996; Kyllerman
et al. 1994). With aging, it tends to evolve from mobile to
fixed dystonia and to be associated with akinetic-rigid
parkinsonism (Gitiaux et al. 2008). Prevention of fixed
dystonia and joint deformities can be done by means of
Table 3 Emergency treatment at home (protocol proposed by GDG)
A. Oral carbohydrates
a Maltodextran
Age (years) % kcal/100 mL KJ/100 mL Volume (mL) per day orally
Up to 0.5 10 40 167 min. 150/kg
0.5-1 12 48 202 120/kg
1-2 15 60 250 100/kg
2-6 20 80 334 1200-1500
6-10 20 80 334 1500-2000
>10 25 100 418 2000-2500
B. Protein intake
Natural protein Stop for 24 to a maximum of 48 hours, then reintroduce and increase stepwise until the amount of maintenance treatment
is reached within 48 (-72) hours. Prolongation of inadequately low protein intake increases the risk of protein
catabolism.
AA mixtures
b If tolerated, AA mixtures should be administered according to maintenance therapy (see also Table 1)
C. Pharmacotherapy
L-Carnitine Double carnitine intake: eg 200 mg/kg per day p.o. in infants
Antipyretics If body temperature raises above 38.5°C (101 F), antipyretics, such as ibuprofen or paracetamol (each 10-15 mg/kg per
single dose, 3-4 doses daily, maximum daily dose 60 mg/kg body weight) should be administered.
aSolutions should be administered every 2 hours day and night.
bIf neonates and infants also receive a lysine-free, tryptophan-reduced amino acid supplement, this can be continued but should be fortified by
maltodextran. Patients should be re-assessed every 2 hours.
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cological and surgical treatments.
Statement #11. In all patients with GA-I, expert
neurological evaluation should be performed by a
neuropediatrician and/or later on by a neurologist to
identify clearly the kind and severity of movement
disorder. In addition, dietitians, physicotherapists, occu-
pational therapists, orthopedists, seating and speech
specialists and providers of communication aids, should
be consulted to provide multi-disciplinary support for
children with movement disorders (GCP).
Dystonia rating scales
Objective assessment of the complex movement disorder in
symptomatic patients is important to evaluate the efficacy
of treatment and to adjust the dosage of medications. One
study (Heringer et al. 2010) however has identified
limitations in the use of the Barry-Albright dystonia rating
scale (Monbaliu et al. 2010; Barry et al. 1999) since it
likely underestimated the severity of the movement disorder
in infants and young children.
Drug therapy
Movement disorders in GA-I are very difficult to treat, and
many of the drugs used have not been studied systematically
(Burlina et al. 2004). Previous studies have shown that
baclofen and benzodiazepines are benefical in the majority of
symptomatic patients and are recommended for first-line
treatment.
Baclofen Baclofen is generally used for symptomatic
treatment of spasticity and also for the long-term
treatment of dystonia in GA-I. Together with diazepam
it is the most widely used and efficacious drug in GA-I
(Hoffmann et al. 1996) and with beneficial effects in 85%
of symptomatic patients (Kyllerman et al. 1994). Oral
baclofen should be used in dosages according to general
recommendations. Intrathecal baclofen administration has
been used with success in a few children with severe
Table 4 Emergency treatment in hospital (protocol proposed by GDG)
A. Intravenous infusions
Glucose Age (years) Glucose (g/kg per day IV)
0-1 (12-) 15
1-3 (10-) 12
3-6 (8-) 10
6-10 (6-) 8
>10 3-6
Insulin If persistent hyperglycemia>150 mg/dL (> 8 mmol/L) and/or glucosuria occurs, start with 0.05 IE insulin/kg per h IVand
adjust the infusion rate according to serum glucose
B. Protein intake
Natural protein Stop for 24 to a maximum of 48 hours, then reintroduce and increase stepwise until the amount of maintenance treatment is
reached within 48 (-72) hours. Prolongation of inadequately low protein intake increases the risk of protein catabolism.
AA mixtures
a If tolerated, lysine-free and tryptophan-reduced AA mixtures should be administered orally or by nasogastric tube
according to maintenance therapy (see also Table 1).
C. Pharmacotherapy
L-Carnitine (50-) 100 (-200) mg/kg per day i.v. – adjusted to oral dosage (see Table 1)
Antipyretics If body temperature rises above 38.5°C (101 F), antipyretics, such as ibuprofen or paracetamol (each 10-15 mg/kg per
single dose, 3-4 doses daily, maximum daily dose 60 mg/kg body weight) should be administered.
Sodium bicarbonate If acidosis; alkalination of urine also facilitates urinary excretion of organic acids
D. Monitoring
Blood Glucose, blood gases, electrolytes, calcium, phosphate, complete blood cell count, creatinine, urea nitrogen, C-reactive
protein, amino acids
b, carnitine, blood culture (if applicable), amylase/lipase
c, creatine kinase
c.
Urine Ketone bodies, pH
Vital signs Heart rate, blood pressure, temperature, diuresis; Glasgow Coma Scale if reduced consciousness; assessment for
neurological signs (hypotonia, irritability, rigor, dystonia)
aLysine-free, tryptophan-reduced amino acid mixtures should be supplemented with minerals and micronutrients.
bDuring the recovery phase.
cIn severe illness to detect pancreatitis (amylase/lipase) or rhabdomyolysis (creatine kinase).
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over-sedation.
Benzodiazepines Diazepam(positiveeffectinmorethan90%
of symptomatic patients) and clonazepam have been success-
fully used in treating dystonia (Hoffmann et al. 1996;
Kyllerman et al. 1994; Kyllerman et al. 2004). Dosages
should be administered according to general recommenda-
tions. In patients in whom the severity of symptoms is highly
variable the dosage can be adjusted daily within a given
range. Intermittent treatment may be required to prevent
tachyphylaxis.
If patients do not benefit from treatment with baclofen and/
or benzodiazepines or adverse effects occur, anticholinergic
d r u g ss h o u l db ec o n s i d e r e da ss e c o n dl i n em e d i c a t i o n .
Anticholinergic drugs Trihexyphenidyl can be effective in
treatingdystonicsymptomsbuttherearefewreportsonitsuse
in GA-I (Burlina et al. 2004). In children, trihexiphenidyl has
been mainly used as a symptomatic treatment for dystonic
cerebral palsy. Although the response to trihexiphenidyl
treatment seems best in adolescents and adults, it may also
be safe and effective in children if sufficient time is given to
respond and the dosage is increased slowly. However,
secondary effects are common, and it may worsen symptoms
in patients with hyperkinetic forms of dystonia, as seen in
GA-I (Rice and Waugh 2009;S a n g e re ta l .2007). Adverse
effects such as blurred vision and dry mouth are usually
temporary. Memory deficit and confusion usually persist and
require a reduction of the dosage. Periodic ocular tonometry
is recommended for adult patients.
Botulinum toxin Botulinum toxin type A may be useful to
prevent hip dislocation and disabling limb dystonia (Burlina
et al. 2004). Some patients may develop immunity against
the toxin, precluding further therapy; therefore, botulinum
toxin is usually administered every three to six months to
minimize the formation of antibodies against the toxin.
Drugs for the movement disorderof no proven benefit or with
adverse effects Some antiepileptic drugshavebeenusedin the
past (Hoffmann et al. 1996; Kyllerman et al. 1994; Kyllerman
et al. 2004;Y a n n i c e l l ie ta l .1994): Vigabatrin and valproate
had little effect (i.e., 10-25% symptomatic patients showed a
therapeutic benefit). Vigabatrin has putatively severe adverse
effects (peripheral visual field defects). Valproate effectively
may promote disturbances in the mitochondrial acetyl-CoA/
CoA ratio. Therefore, valproate and vigabatrin should not be
used for the treatment of movement disorder in GA-I.
Carbamazepine was always unequivocally ineffective. There
is no improvement of the extrapyramidal syndrome with L-
DOPA. In a few patients, amantadine was used but there was
no improvement in dystonic movement disorder.
Statement #12. Baclofen and benzodiazepines as
monotherapy or in combination should be used as
first line drug treatment for focal and generalized
dystonia. Intrathecal baclofen should be considered as
additionaltherapyforgeneralizeddystoniaandspasticity.
Trihexyphenidyl should be considered as second line
treatment for dystonia, particularly in adolescents and
adults. Botulinum toxin A should be considered as
additional therapy for severe focal dystonia (grade D).
Neurosurgery
Stereotactic surgery (pallidotomy) for severe generalized
dystonia has been reported for three patients. The results
reported in two patients were unsatisfactory (Strauss et al.
2003), whereas short-term improvement in dystonic symp-
toms were described in one (Rakocevic et al. 2004). The
results of deep brain stimulation of the globus pallidus
internus has not yet been reported in patients with dystonia
due to GA-I.
Antiepileptic therapy
Epilepsy is not a major symptom in GA-I, whereas single
seizures may be observed during an acute encephalopathic
crisis (Greenberg et al. 2002;K ö l k e re ta l .2006; Kyllerman et
al. 2004; Strauss et al. 2003). In one child, however, epileptic
seizures were the sole presenting feature (McClelland et al.
2009), but dystonic movements may be mistaken as seizures
(Cerisola et al. 2009). No study has compared the relative
efficacy of antiepileptic agents in GA-I. However, as
mentioned before valproate should not be used because of
potential effects on mitochondrial function.
Statement #13. Diagnosis, choice of antiepileptic drug
therapy and management of seizures in GA-I should
follow existing guidelines – except for the use of
valproate which should be avoided in this condition.
The diagnosis of epilepsy and choice of antiepileptic
drugs should be made by a pediatric neurologist or
pediatrician with expertise in childhood epilepsy. In
adulthood, patients with epilepsy should be followed
and antiepileptic therapy should be monitored by an
adult neurologist (GCP).
Subdural haemorrhage and arachnoid cysts
Diagnosis Subdural haemorrhage may occur at any age in
GA-I but peaks during the age of maximal extent of
macrocephaly, i.e., late infancy (Brismar and Ozand 1995;
Köhler and Hoffmann 1998; Woelfle et al. 1996). Minor
J Inherit Metab Dis (2011) 34:677–694 689head traumas with disruption of elongated bridging veins
have been suggested as underlying mechanisms. The exact
frequency of subdural bleeding is unknown, since affected
patients may remain asymptomatic. Subdural haemorrhage
in GA-I may be mistaken with shaken baby syndrome and
vice versa (Hartley et al. 2000;M o r r i se ta l .1999).
Bitemporal arachnoid cysts have been described in some
affected patients and should result in a high suspicion for
GA-I (Hald et al. 1991; Jamjoom et al. 1995; Lücherath et
al. 2000; Martinez-Lage et al. 1994), whereas unilateral
arachnoid cysts are a rare occurence in this disease.
Statement #14. Children with subdural haemorrhage
and/orbitemporalarachnoidcystsshouldbeinvestigated
for glutaric aciduria type I, in particular if occuring in
combination with macrocephaly and/or a movement
disorder (grade D).
Statement #15. Glutaric aciduria type I should be
excluded in children with suspected shaken baby
syndrome using the recommendations for selective
screening (see also statement #5, Fig. 1) (grade D).
Neurosurgery Neurosurgical interventions have been per-
formed in a small number of affected patients with
arachnoid cysts and subdural haemorrhage (Hald et al.
1991; Lütcherath et al. 2000; Martinez-Lage et al. 1994;
Woelfle et al. 1996). The majority of these patients had a
poor neurological outcome or sometimes with significant
worsening of the neurological symptoms in the context of
the neurosurgical intervention. In particular, neurosurgical
interventions in undiagnosed patients who do not receive
specific metabolic treatment neurosurgical interventions can
precipitate an encephalopathic crisis. Subdural haemorrhage
may regress without neurosurgical intervention.
Statement#16.Neurosurgical intervention forarachnoid
cysts and subdural haemorrhages in affected patients
should be undertaken very cautiously in close consul-
tation with the pediatric neurosurgeon (grade D).
The metabolic management during and after any surgical
interventions should be based on recommendations for
metabolic treatment and should be supervised by a
metabolic specialist (see also statements #6-10).
Monitoring therapy
Investigative procedures
General aims
The aim of regular therapy monitoring is to assess the
efficacy of treatment and to identify complications or side
effects. In children, it should also include an evaluation of
psychomotor development and growth. In general, moni-
toring should include those tests that influence therapeutic
decisions and should be preventive in its overall approach.
However at present, there is no reliable marker that predicts
the outcome of GA-I.
Clinical monitoring
Clinical monitoring should be frequent, and consist of a wide
variety of investigations, including general pediatric parame-
ters (e.g., anthropometrics, developmental milestones), neu-
rological assessment, and specific psychological tests.
Although overall average cognitive outcomes may be normal,
subtle deficits, mainly in speech development and fine motor
function, may be observed in individual patients (Beauchamp
et al. 2009; Harting et al. 2009). Expertise from general
pediatricians, metabolic specialists, and dietitians from
metabolic centers should be included into the evaluation of
patients in an integrative way. In addition, consultations from
other specialties (e.g., child neurologists, psychologists,
physiotherapists) should be considered as necessary.
Statement #17. Therapy should be accompanied by
regular professional monitoring. Monitoring should
be intensified at any age if there are new complica-
tions (disease- or therapy-related) or non-adherence to
treatment (GCP).
Routine biochemical monitoring
Table 5 summarizes recommended best practice based on
the clinical experience of the GDG on routine laboratory
monitoring in GA-I. At present, there is no reliable
biochemical marker that is useful for the monitoring of
maintenance treatment in GA-I and there is considerable
variation in expert opinion (Mühlhausen et al. 2004).
Organic acids A decrease in the urinary concentrations of
GA and 3-OH-GA has been demonstrated in high excretors
following dietary treatment (Hoffmann et al. 1991; Hoffmann
et al. 1996; Strauss et al. 2003), whereas this biochemical
response is usually not found in the urine of low excretors
(Greenberg et al. 2002). At present, there is no evidence that
urinary concentrations of GA and 3-OH-GA correlate with
the long-term clinical outcome (Christensen et al. 2004;
Kölker et al. 2006).
Statement #18. Urine analysis of GA and 3-OH-GA is
not informative for therapy monitoring (grade D).
Amino acids Analysis of all essential amino acids in
plasma is useful to ensure that nutrition is not being
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in children with feeding problems (Müller and Kölker
2004; Yannicelli et al. 1994). Tryptophan should be
assayed by specific HPLC analysis (or MS/MS analysis)
as conventional amino acid analysis is not satisfactory
(Krstulovic et al. 1977; Laich et al. 2002).
Statement #19. Amino acids in plasma (ideally 3-4 h
postprandially) should be monitored during dietary
treatment (grade D).
Carnitine status L-Carnitine supplementation prevents sec-
ondary depletion of free carnitine and is thought to
contribute to improved outcome (Heringer et al. 2010;
Kölker et al. 2006; Seccombe et al. 1986). Carnitine status
in plasma can be assessed using HPLC or MS/MS analysis,
and gives valuable information on compliance. MS/MS
analysis in dried blood spots is also useful to detect
secondary carnitine depletion, although less accurately than
plasma analysis.
Statement #20. Carnitine status in plasma should be
monitored in all patients to detect secondary carnitine
depletion (grade D).
Acylcarnitine profile Assessment of C5DC and other
acylcarnitines in dried blood spots is of little value in regular
biochemical monitoring. C5DC will increase markedly with
the start of L-carnitine supplementation.
Additional biochemical monitoring Analysis of other
parameters, such as complete blood cell count, albumin,
calcium, phosphate, vitamin D status, ferritin, and serum
transaminases may be helpful for routine surveillance
(Yannicelli et al. 1994).
Biochemical monitoring during acute illness
Vomiting, diarrhoea and reduced intake of nutrients and
fluids increase the risk of dehydration, electrolyte abnor-
malities, acidosis, and subsequently acute encephalopathic
crises (Bjugstad et al. 2000; Hoffmann et al. 1996; Kölker
et al. 2006; Kyllerman et al. 2004; Strauss et al. 2003).
Imbalances in the metabolic state, hydration and serum
electrolytes, and complications should be identified on
admission and emergency treatment adjusted accordingly.
Neuroradiological monitoring
Cranial MRI in affected patients often demonstrates a
characteristic pattern of gray and white matter changes
and abnormalities of CSF spaces that should prompt a
high suspicion for the diagnosis of GA-I (Suppl. Table 4).
However, striatal and extrastriatal MR abnormalities may
be highly variable and may progress in a different way and
with discrepant velocity (Harting et al. 2009). MRI
studies, in particular those using echo-planar imaging
spin-echo or apparent diffusion coefficient maps, detect
striatal lesions earlier and more reliably than CT scans
(Brismar and Ozand 1995; Desai et al. 2003; Elster 2004;
Neumaier-Probst et al. 2004; Oguz et al. 2005;S t r a u s se t
al. 2007;T w o m e ye ta l .2003). Some of these neurora-
diological changes can also be detected by ultrasound
(Forstner et al. 1999), even already during the last
trimester of pregnancy (Lin et al. 2002;M e l l e r i oe ta l .
Table 5 Routine biochemical monitoring in glutaric aciduria type I (basic schedule proposed by GDG)
Parameter Rationale Frequency at age
0-2 years 2-6 years > 6 years
Amino acids (plasma) General nutritional status Every 1-2 months Every 3 months Every 6-12 months
Tryptophan (plasma; HPLC) Tryptophan depletion In children with feeding problems; or if clinical presentation
suggests tryptophan depletion; or if amino acid supplements
do not contain tryptophan.
Carnitine (plasma or serum) Avoid depletion, check for
non-adherence
Every 1-2 months Every 3 months Every 6-12 months
Complete blood cell count, ferritin Routine surveillance, avoid depletion
of iron, folate, or cobalamin
Every 6 months Every 6 months Every 6-12 months
Albumin General nutritional status If concerns exist about the nutritional status and in children
with feeding problems
Calcium, phosphate, alkaline phosphatase Bone status
a, check for compliance Every 3 months Every 6 months Every 12 months
Transaminases Routine surveillance Every 3 months Every 6 months Every 12 months
a If inadequate bone mineralization is suggested, additional tests are required (e.g., vitamin D status, parathyroid hormone, radiological
investigations for bone age and density).
J Inherit Metab Dis (2011) 34:677–694 6912008). The benefit of serial MRI investigations is unclear
and is not considered essential for regular monitoring. As
long as the fontanelle is open, cranial ultrasound can be
used instead (but may miss hygromas).
Statement #21. Neuroradiologic investigations should
be performed in case of neurologic deteroriation but
are not generally recommended for regular follow-up
monitoring (GCP).
Although many questions remain regarding the patho-
genesis and treatment of GA-I, much has been learned since
publication of the initial version of this guideline. Basic and
clinical research, as well as the diligent recording of the
natural history of the disease in many patients, has led to
improvements in patient outcomes. These advances in our
knowledge and the quality of evidence regarding treatment
of GA-I have been incorporated into these revised guide-
lines. However, in spite of recent advances, future studies
will be required to evaluate long-term outcome, better
characterize atypical patients, and develop reliable diagnos-
tic algorithms for patients with a low excretor phenotype.
Further evidence regarding dietary management and therapy
monitoring is also needed. The results of these and other
studies will increase the level of evidence of future guide-
lines, which in the long-term we hope will improve the
outcome of all patients with GA-I.
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